<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443818</url>
  </required_header>
  <id_info>
    <org_study_id>OLIVIER-FAIVRE Sirolimus</org_study_id>
    <nct_id>NCT02443818</nct_id>
  </id_info>
  <brief_title>Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      It was found that people who have an excessive growth in one or more parts of their body and
      normal growth in other parts, may have a change in genes responsible for controlling cell
      growth. This genetic discovery identified a possible treatment for this overgrowth, called
      Sirolimus.

      This is a pilot study, which help the investigators prepare a larger international study,
      which will aim to determine whether a treatment based Sirolimus is able to stop the excessive
      growth of one or more parties of their body in people who carry a genetic change in the
      PIK3CA gene (phosphatidylinosilol-3-kinase encoded by the gene PIK3CA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of participation is 15 months:

        -  Visit screening: blood test, pre-clinical evaluation, urine collection and chest X-ray.

        -  First 6 months: participants will have their overgrowth monitored. This step includes 2
           visits taking place at the University Hospital of Dijon: complete clinical evaluation,
           MRI of the body part by the overgrowth and Dual-energy X-ray absorptiometry (DXA).

        -  Next 6 months: participants will take Sirolimus. This step includes 2 visits (4 and 13
           weeks after the start of treatment at local hospital): blood test, urine collection and
           clinical evaluation.

      and 1 end of study visit after 6 months of treatment taking place at the University Hospital
      of Dijon: blood test, complete clinical evaluation, urine collection, MRI and DXA.

      Participants will have several blood and urine tests between visits (1 and 2 weeks after the
      start of treatment at a local laboratory).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the relative percentage of the excess tissue volume evolution at the affected site by volumetric MRI.</measure>
    <time_frame>Change from baseline at 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure sites of overgrowth by DXA, MRI and circumferential measurements</measure>
    <time_frame>Change from baseline at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine optimal sirolimus dosing algorithms by plasma assay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation and surgery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measured by a questionnaire in the pre- and post-treatment periods</measure>
    <time_frame>At 6 and 12 months</time_frame>
    <description>The WHO-QOL-BREF questionnaire will be used for adults. For children, PedsQL™ questionnaire for children and parents report for children questionnaires will be used</description>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Segmental Overgrowth Disorders Due to PIK3CA</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-zygotic PIK3CA mutation

          -  Age: 3-65 years

          -  Measurable overgrowth, in current progression or with clinical history of overgrowth
             progression

          -  Patient clinically stable

          -  Presence of a disability, social or cosmetic impairment requiring treatment from the
             patient perspective,

          -  Written informed consent form signed and dated by the subject or by the patient's
             legal representative

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Women and men of reproductive age without any effective method of contraception
             (during treatment and up to 12 weeks after sirolimus discontinuation)

          -  Hypersensitivity to the active substance (sirolimus) or to any of the excipients

          -  Impossibility to obtain written informed consent form signed by the subject or the
             patient's legal representative, or vulnerable adults

          -  Treatment with Sirolimus in the last 4 weeks before the trial

          -  Personal history of malignancy or current investigations for suspected malignancy

          -  Active skin infection requiring antibiotics or antiviral treatments

          -  HIV or hepatitis B or C infection

          -  Past history of Mycobacterium tuberculosis infection

          -  Active pneumopathy

          -  Uncontrolled infection

          -  Chronic liver disease (ASAT or Alanine amino transférase (ALAT)&gt; 3 times upper normal
             limit)

          -  Stage 3 (or more) chronic renal insufficiency (eGFR&lt; 60mls/min)

          -  Neutropenia with neutrophiles &lt; 1.0 x10^9/L

          -  Uncontrolled dyslipidemia

          -  Inability to attend study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence OLIVIER-FAIVRE</last_name>
    <phone>3 80 29 53 13</phone>
    <phone_ext>+33</phone_ext>
    <email>laurence.faivre@chu-dijon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre VABRES</last_name>
    <phone>3 80 29 33 36</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre.vabres@chu-dijon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic MARTIN</last_name>
      <phone>2 41 35 39 10</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Ludovic MARTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - GH Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier LACOMBE</last_name>
      <phone>5 57 82 03 63</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Didier LACOMBE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny MORICE-PICARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence OLIVIER-FAIVRE</last_name>
      <phone>3 80 29 53 13</phone>
      <phone_ext>+33</phone_ext>
      <email>laurence.faivre@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre VABRES</last_name>
      <phone>3 80 29 33 36</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre.vabres@chu-dijon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence OLIVIER-FAIVRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre VABRES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berthille BONNIAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine JEUDY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Benoit COURCET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice MASUREL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daphnée LEHALLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christel THAUVIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien THEVENON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine VINCENTDELORME</last_name>
      <phone>3.20.44.49.11</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier BESSIS</last_name>
      <phone>4 67 33 69 06</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Christine COUBES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier BESSIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Brabois Chu Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Claire BURSZTEJN</last_name>
      <phone>3 83 15 71 38</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Anne-Claire BURSZTEJN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital mère-enfant de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand ISIDOR</last_name>
      <phone>2 40 08 32 45</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Bertrand ISIDOR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie VINCENT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smail HADJ-RABIA</last_name>
      <phone>1 44 49 43 37</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Smail HADJ-RABIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geneviève BAUJAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne AMIEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL Lyon - CH Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice PHAN</last_name>
      <phone>4 27 85 61 26</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Alice PHAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Cardiovasculaire et Métabolique - Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliette MAZEREEUW-HAUTIER</last_name>
      <phone>5 67 77 81 41</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Juliette MAZEREEUW-HAUTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annabel MARUANI</last_name>
      <phone>2 47 47 46 25</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Annabel MARUANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie ARPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

